Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Brain Stent Eases Pseudotumor Symptoms

By HospiMedica International staff writers
Posted on 01 Apr 2013
A new study shows that an endovascular stent placed in the transverse sinus (TS) significantly reduces the pressure gradient of pseudotumor cerebri (PTC), improving tinnitus as well as visual function.

Researchers at the Uniformed Services University of the Health Sciences (USUHSj Bethesda, MD, USA) and Johns Hopkins University (Baltimore, MD, USA) conducted a study involving 12 patients with PTC. More...
All patients had initial neurological, neuro-ophthalmological, and imaging assessments; regardless of the findings, all were treated with medical therapy. If medical therapy failed and TS stenosis was detected on contrast-enhanced magnetic resonance imaging (MRI) or computerized tomography (CT) venography, catheter cerebral angiography with venous manometry was performed. If a mean pressure gradient of 4 mmHg or greater was present, unilateral TS stenting was performed.

The results showed that TS stenting significantly decreased the PTC pressure gradient in all cases, and that unilateral stenting was sufficient to reduce pressure gradients, even when the stenosis was bilateral. At a mean follow-up of 16 months, tinnitus had improved in all patients, and 10 of 12 patients had improvement in visual function. Seven of the patients also had significant improvement in headaches. The study was published on March 14, 2013, in the Journal of Neuro-Ophthalmology.

“Following stenting, headaches resolved completely in two patients and improved in five, but persisted in the remaining five patients,” concluded lead author Martin Radvany, MD, of USHUS, and colleagues. “Of five patients in this series who continued to have headaches despite normalization of CSF pressure after stenting, four responded to migraine prophylactic medications.”

Pseudotumor cerebri presents as raised intracranial pressure (ICP) with normal cerebrospinal fluid (CSF) analysis, and without clinical or imaging evidence of a space-occupying pathology. Around 10%–20% of patients will experience vision loss caused by prolonged papilledema, with secondary optic nerve atrophy. Conventional treatment consists of oral acetazolamide, which is limited in long-term use by its side effects. Surgical options include optic nerve sheath fenestration and CSF diversion procedures.

Related Links:

Uniformed Services University of the Health Sciences
Johns Hopkins University



Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Medical Monitor
VITALMAX 4100SL
Infant Resuscitator
Easypuff
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.